Stock·LSE·£
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and gastroenterology. The company's current commercial offerings include Gvoke, a pre-mixed liquid glucagon formulated for managing severe hypoglycemia. It also provides Keveyis, a specific therapy for various forms of primary periodic paralysis, including hyperkalemic and hypokalemic types. Additionally, Xeris markets Recorlev, a cortisol synthesis inhibitor approved for adults experiencing endogenous hypercortisolemia as a result of Cushing's syndrome. Beyond its existing portfolio, Xeris Biopharma maintains an active pipeline of development programs. These initiatives aim to broaden the indications and potential applications of its current therapies, as well as to introduce novel products. The creation of these new offerings is supported by the company's proprietary formulation platforms, XeriSol and XeriJect. Established in 2005, the company's corporate headquarters are situated in Chicago, Illinois.
See 0A8E.L price live on your physical desk display. Set alerts with iOS & Android apps.
